SSKN

MKT CAP:$1M

STRATA Skin Sciences, Inc.

Market Cap

$1M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Healthcare·Medical - Devices·🇺🇸·NASDAQ

Stock Price

$0.13-$1.14 (-89.76%)

Apr 21, 2026

Company Details

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central ...

CEO

Dolev Rafaeli

IPO Date

Nov 3, 2005

Website

www.strataskinsciences.com

Key Metrics TTM

Revenue

$31M

-8.5% YoY

Net Income

-$6M

EPS (Diluted)

-$1.01

Free Cash Flow

-$4M

Revenue / Share

$5.21

Gross Margin

57.8%

Operating Margin

-19.7%

Net Margin

-21.1%

FCF Margin

-13.9%

P/S

0.0x

P/E

—

Earnings Reports

Q1 2026

May 13, 2026

PENDING

Q4 2025

Mar 25, 2026

$9M-3.0%EPS $0.01

Q3 2025

Nov 14, 2025

$7M-21.2%EPS -$0.36

Q2 2025

Aug 13, 2025

$8M-9.2%EPS -$0.60

Q1 2025

May 14, 2025

$7M+0.9%EPS -$0.06

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$7M	$4M	-$2M
Q2 22	$9M	$5M	-$2M
Q3 22	$9M	$6M	-$786.0K
Q4 22	$11M	$7M	$134.0K
Q1 23	$8M	$4M	-$3M
Q2 23	$8M	$4M	-$2M
Q3 23	$9M	$5M	-$615.0K
Q4 23	$9M	$5M	-$3M
Q1 24	$7M	$3M	-$3M
Q2 24	$8M	$5M	-$486.0K
Q3 24	$9M	$5M	-$2M
Q4 24	$10M	$6M	-$4M
Q1 25	$7M	$4M	-$2M
Q2 25	$8M	$4M	-$2M
Q3 25	$7M	$4M	-$2M
Q4 25	$9M	$6M	$37.0K

Valuation

Quarter	P/S	P/E
Q1 22	17.1x	—
Q2 22	10.9x	—
Q3 22	8.4x	—
Q4 22	7.8x	—
Q1 23	10.1x	—
Q2 23	10.0x	—
Q3 23	5.8x	—
Q4 23	6.1x	—
Q1 24	4.3x	—
Q2 24	3.7x	—
Q3 24	3.2x	—
Q4 24	3.3x	—
Q1 25	3.3x	—
Q2 25	3.1x	—
Q3 25	3.1x	—
Q4 25	2.0x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$353.0K	-$1M
Q2 22	-$56.0K	-$887.0K
Q3 22	-$694.0K	-$1M
Q4 22	-$5.0K	-$2M
Q1 23	-$1M	-$3M
Q2 23	$175.0K	-$756.0K
Q3 23	-$997.0K	-$2M
Q4 23	$2M	-$347.0K
Q1 24	-$804.0K	-$2M
Q2 24	$591.0K	$246.0K
Q3 24	-$302.0K	-$364.0K
Q4 24	$703.0K	$199.0K
Q1 25	-$550.0K	-$749.0K
Q2 25	-$2M	-$2M
Q3 25	-$64.0K	-$1M
Q4 25	-$239.0K	-$551.0K

Capital Expenditures

Quarter	CapEx
Q1 22	$679.0K
Q2 22	$831.0K
Q3 22	$527.0K
Q4 22	$2M
Q1 23	$1M
Q2 23	$931.0K
Q3 23	$829.0K
Q4 23	$2M
Q1 24	$725.0K
Q2 24	$345.0K
Q3 24	$62.0K
Q4 24	$504.0K
Q1 25	$199.0K
Q2 25	$61.0K
Q3 25	$1M
Q4 25	$312.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+20.8%	+13.7%
Q2 22	+23.3%	+30.0%
Q3 22	+22.1%	+24.7%
Q4 22	+17.1%	+8.2%
Q1 23	+7.5%	+8.7%
Q2 23	-9.4%	-5.4%
Q3 23	-6.0%	-7.2%
Q4 23	-18.0%	+15.9%
Q1 24	-10.7%	-5.0%
Q2 24	+2.2%	-12.6%
Q3 24	-0.6%	+10.4%
Q4 24	+10.2%	+13.8%
Q1 25	+0.9%	-8.5%
Q2 25	-9.2%	+10.8%
Q3 25	-21.2%	-15.9%
Q4 25	-3.0%	-32.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$368.0K	5.2%
Q2 22	$452.0K	5.0%
Q3 22	$455.0K	4.8%
Q4 22	$191.0K	1.8%
Q1 23	$325.0K	4.3%
Q2 23	$352.0K	4.3%
Q3 23	$337.0K	3.8%
Q4 23	$289.0K	3.3%
Q1 24	$112.0K	1.7%
Q2 24	$163.0K	1.9%
Q3 24	$26.0K	0.3%
Q4 24	$126.0K	1.3%
Q1 25	$129.0K	1.9%
Q2 25	$128.0K	1.7%
Q3 25	$0	0.0%
Q4 25	$174.0K	1.9%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$163.0K	$3M	$4M	—
Q2 22	$209.0K	$2M	$4M	—
Q3 22	$216.0K	$3M	$4M	—
Q4 22	$441.0K	$2M	$4M	—
Q1 23	$315.0K	$3M	$4M	—
Q2 23	$374.0K	$2M	$3M	—
Q3 23	$248.0K	$2M	$3M	—
Q4 23	$380.0K	$3M	$3M	—
Q1 24	$241.0K	$3M	$3M	—
Q2 24	$199.0K	$2M	$3M	—
Q3 24	$243.0K	$4M	$3M	—
Q4 24	$200.0K	$3M	$3M	—
Q1 25	$96.0K	$3M	$3M	—
Q2 25	$86.0K	$3M	$4M	—
Q3 25	$172.0K	$3M	$3M	—
Q4 25	$67.0K	—	—	$6M

Revenue Segments

Quarter	Dermatology Procedures Equipment	Dermatology Recurring Procedures
Q1 22	$2M	$5M
Q2 22	$4M	$6M
Q3 22	$4M	$6M
Q4 22	$4M	$7M
Q1 23	$2M	$5M
Q2 23	$3M	$5M
Q3 23	$4M	$5M
Q4 23	$3M	$6M
Q1 24	$2M	$5M
Q2 24	$3M	$5M
Q3 24	$3M	$5M
Q4 24	$4M	$6M
Q1 25	$2M	$5M

Revenue by Geography

Quarter	Domestic	Foreign
Q1 22	$5M	$2M
Q2 22	$6M	$3M
Q3 22	$6M	$3M
Q1 23	$5M	$2M
Q2 23	$6M	$2M
Q3 23	$6M	$3M
Q1 24	$4M	$2M
Q2 24	$5M	$3M
Q3 24	$6M	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$11M	$0	$11M
Q2 22	$10M	$0	$10M
Q3 22	$7M	$0	$7M
Q4 22	$5M	$0	$5M
Q1 23	$3M	$0	$3M
Q2 23	$9M	$0	$9M
Q3 23	$7M	$0	$7M
Q4 23	$7M	$0	$7M
Q1 24	$5M	$0	$5M
Q2 24	$5M	$0	$5M
Q3 24	$7M	$0	$7M
Q4 24	$7M	$0	$7M
Q1 25	$7M	$0	$7M
Q2 25	$6M	$0	$6M
Q3 25	$7M	$0	$7M
Q4 25	$8M	$0	$8M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	35M	+0.9%	+2.6%
Q2 22	35M	+0.1%	+1.2%
Q3 22	35M	0.0%	+1.7%
Q4 22	35M	+0.0%	+1.0%
Q1 23	35M	+0.4%	+0.5%
Q2 23	35M	+0.1%	+0.5%
Q3 23	35M	+0.1%	+0.5%
Q4 23	35M	+0.3%	+0.9%
Q1 24	35M	+0.1%	+0.6%
Q2 24	35M	-0.0%	+0.5%
Q3 24	40M	+15.2%	+15.7%
Q4 24	38M	-5.7%	+8.7%
Q1 25	42M	+9.6%	+19.0%
Q2 25	42M	0.0%	+19.0%
Q3 25	45M	+7.4%	+11.0%
Q4 25	6M	-86.9%	-84.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$61.2K	115
Q2 22	$79.2K	115
Q3 22	$81.9K	115
Q4 22	$93.0K	114
Q1 23	$66.4K	114
Q2 23	$72.4K	114
Q3 23	$77.6K	114
Q4 23	$87.8K	99
Q1 24	$68.2K	99
Q2 24	$85.2K	99
Q3 24	$88.9K	99
Q4 24	$90.3K	106
Q1 25	$64.3K	106
Q2 25	$72.3K	106
Q3 25	$65.4K	106
Q4 25	$81.5K	114

Revenue / Employee